Evommune Sells 4,494,279 Shares in Private Placement at $27.88
Evommune announced that it has entered into a securities purchase agreement to sell 4,494,279 shares of its common stock to a select group of new and existing mutual funds and dedicated healthcare institutional investors in a private placement. The purchase price of each share of common stock is $27.88. Evommune anticipates the gross proceeds from the private placement to be approximately $125 million, before deducting any transaction-related expenses. Morgan Stanley & Co. LLC, Leerink Partners LLC, Evercore ISI, Cantor Fitzgerald & Co., and William Blair & Company, L.L.C. acted as placement agents for the private placement.
